Lotus medicinals (1795:TT, the “Company”), a multinational pharmaceutical company, announced today that its board of directors has approved the acquisition of the trademark, marketing authorization and manufacturing expertise of pemetrexed 100 mg and 500 mg under the brand name Alimta in Taiwan to the $62 million out Eli Lilly and Co (‘Lilly‘).
Immediately upon closing of the transaction, the Company will acquire Alimta’s business Taiwan. The closing of this transaction is subject to customary closing conditions.
Alimta is indicated for the treatment of non-small cell lung cancer (‘NSCLC’) and malignant pleural mesothelioma (‘MPM’) and is a first-line treatment for NSCLC with strong brand loyalty. According to IQVIA data, Alimta’s total sales are in Taiwan for the last 12 months December 31, 2021 were about $48 millionpowered by the major hospitals and medical centers in Taiwan.
Lung cancer has been one of the leading causes of death for years Taiwan for decades, resulting in more than 15,000 patients suffering from the disease every year.
Petar Vazharov, Lotus Chief Executive Officer, said: “Lotus is committed to improving the quality of life for cancer patients by providing access to more treatment alternatives. The acquisition of Alimta supports our mission and enables Lotus to become a leading player in oncology in one of its core markets Asia. Lotus has built an extensive portfolio in the lung cancer drug market over the past 6 years, including complex generics such as the internally developed oral formulation of vinorelbine and in-licensed NCEs such as Zepzelca (lurbinectedin).’
The Lotus Board of Directors has approved the asset purchase Lilly‘s Alimta including trademark, marketing authorization and manufacturing know-how for the territory of Taiwan to the $62 million.
Alimta is a leading branded product in Taiwan approved as a first-line treatment for non-small cell lung cancer with sales in 2021 $48 million according to IQVIA data. Lung cancer is one of the leading causes of death in Taiwan for decades with more than 15,000 new patients suffering from the disease
The acquisition allows Lotus to establish itself as a major player in oncology Taiwan by adding a leading branded product to its existing portfolio of cancer medicines and will increase market penetration of its other products, including Zepzelca, vinorelbine softgel and erlotinib.
Email: [email protected]
(C) 2022 Electronic News Publishing, source ENP Newswire